Switch Therapeutics is an emerging precision neuroscience biotechnology company pioneering a new type of RNAi medicine, with the goal of treating a range of CNS diseases. The company is developing biomarker-gated, innovative genetic medicines to transform the treatment of central nervous system diseases. Their proprietary platform, CASi (Conditionally Activated siRNAs), combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.

Switch Therapeutics

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch’s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. 

Based on the scientific discovery of Switch’s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. 

To date, Switch has raised $52M in funding through Series A, and the company’s South San Francisco based team has continued to grow as its research has advanced. 

UCB Ventures

Upfront Ventures

Ono Venture Investment

PhiFund Ventures

Digitalis Ventures

Dolby Family Ventures

Eli Lilly & Company Foundation

Freeflow Ventures

Insight Partners

Bold Capital Partners

That’s a wrap on #JPM2024 🎉
 
Thank you to JPM organizers and everyone we had a chance to meet with. We look forward to what’s in store for #biotech in 2024.
 
#JPM24

We look forward to attending #JPM2024 and connecting with investors, industry leaders and discussing the latest in #biotech with our peers.

Let us know if you’re attending this year’s conference and would like to connect to learn more about our novel CASi platform.

 #JPM24

Today, Switch Therapeutics welcomes Charles Allerson, as our new Chief Technology Officer. 🎉

Dr. Allerson joins our team with extensive expertise in oligonucleotide chemistry and #rna-based therapeutics. With the goal of progressing our proprietary CASi platform into multiple IND-enabling studies in 2024, Charles will be a key leader to help propel the team forward. We are excited for what lies ahead for Switch Therapeutics in 2024 and beyond. 

Learn more about Switch and Dr. Allerson here: https://lnkd.in/ed7uNY5X

Metric
Company Name	Switch Therapeutics
Symbol
MSH ID	COM:SWITCHTHERA
Market	PRIVATE
Sector	Healthcare
Industry	Biotechnology Research
Country	US
Stage
Employee Count	38
Website	switchthera.com
LinkedIn	switch-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	48.22
28-Day Growth Score	11.92
90-Day Growth Score	47.77
365-Day Growth Score	59.20

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:SWITCHTHERA

Switch Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue